Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 31.5136 USD 5.15%
Market Cap: 5.1B USD
Have any thoughts about
Alkermes Plc?
Write Note

Gross Margin
Alkermes Plc

83.2%
Current
83%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.2%
=
Gross Profit
1.3B
/
Revenue
1.5B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IE
Alkermes Plc
NASDAQ:ALKS
4.8B USD
83%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
35.8B EUR
89%
Country IE
Market Cap 4.8B USD
Gross Margin
83%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.8B EUR
Gross Margin
89%
No Stocks Found

Alkermes Plc
Glance View

Market Cap
5.1B USD
Industry
Biotechnology

Alkermes Plc, an Irish biopharmaceutical company, has carved its niche at the intersection of neuroscience and oncology, a strategic pivot that underscores its commitment to addressing unmet medical needs. The firm's focus lies in the development of innovative pharmaceuticals that offer hope and efficacy where other treatments may fall short. These include proprietary products as well as collaborations with more established pharmaceutical entities. At the heart of Alkermes' operations is its R&D engine, which drives the development of cutting-edge treatments leveraging the company's proprietary technology platforms. This not only underpins its internal drug development pipeline but also enhances its value proposition in collaborations with partner companies, fostering a symbiotic environment where innovation and mutual benefit intersect. The way Alkermes generates revenue is multifaceted, reflecting its dynamic business model. The company earns through product sales from its proprietary medicines, which are tailored for chronic diseases such as schizophrenia, addiction, and multiple sclerosis. Moreover, a significant portion of its income is derived from strategic collaborations and royalty agreements, where it grants larger pharmaceutical companies access to its technology platforms or the commercial rights to certain drug formulations. These alliances often entail milestone-based payments and ongoing royalties contingent upon sales performance, providing Alkermes with a steady revenue stream and reducing its dependency on the success of any single product. By balancing its own product development with these partnerships, Alkermes secures financial robustness while maintaining its position at the forefront of pharmaceutical innovation.

ALKS Intrinsic Value
23.7012 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.2%
=
Gross Profit
1.3B
/
Revenue
1.5B
What is the Gross Margin of Alkermes Plc?

Based on Alkermes Plc's most recent financial statements, the company has Gross Margin of 83.2%.